SCHEMBL5074353

SCHEMBL5074353

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccccc1OC

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
BCHE P06276 10/20 0.40
ACHE P22303 8/20 0.40
TSHR P16473 2/20 0.40
CASR P41180 1/20 0.40
MAOB P27338 3/20 0.39
CYP19A1 P11511 1/20 0.38
TACR1 P25103 1/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
KMT2A Q03164 1/20 0.37
APP P05067 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134673 0.94 C5AR1 (0.43) C5AR1BCHEACHETSHRCASR
SCHEMBL5136715 0.93 C5AR1 (0.43) C5AR1BCHECASRMEN1KMT2A
SCHEMBL5138021 0.91 C5AR1 (0.43) C5AR1TSHRCASRTP53MAPT
SCHEMBL5069962 0.91 BCHE (0.45) C5AR1BCHEACHETSHRCASR
SCHEMBL5135193 0.91 BCHE (0.43) C5AR1BCHEACHETSHRCASR
SCHEMBL5136651 0.91 C5AR1 (0.43) C5AR1ACHETSHRTP53KDM4E
SCHEMBL5136562 0.90 ALDH1A1 (0.46) C5AR1ACHETSHRTP53MAPT
SCHEMBL649706 0.89 C5AR1 (0.41) C5AR1BCHETSHRCASRKDM4E
SCHEMBL4772610 0.89 C5AR1 (0.41) C5AR1BCHEACHETSHRCASR
SCHEMBL651094 0.89 TSHR (0.50) C5AR1TSHRKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed